APPH Stock Overview
Engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Apontis Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.52 |
| 52 Week High | €10.00 |
| 52 Week Low | €3.38 |
| Beta | 1.24 |
| 11 Month Change | 1.28% |
| 3 Month Change | 40.00% |
| 1 Year Change | 181.66% |
| 33 Year Change | -52.40% |
| 5 Year Change | n/a |
| Change since IPO | -49.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| APPH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.4% | -5.0% | -1.3% |
| 1Y | 181.7% | -22.0% | 7.4% |
Return vs Industry: APPH exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: APPH exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| APPH volatility | |
|---|---|
| APPH Average Weekly Movement | 15.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: APPH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: APPH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 177 | Bruno Wohlschlegel | apontis-pharma.de |
Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany.
Apontis Pharma AG Fundamentals Summary
| APPH fundamental statistics | |
|---|---|
| Market cap | €81.47m |
| Earnings (TTM) | -€7.08m |
| Revenue (TTM) | €40.63m |
2.0x
P/S Ratio-11.5x
P/E RatioIs APPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APPH income statement (TTM) | |
|---|---|
| Revenue | €40.63m |
| Cost of Revenue | €15.72m |
| Gross Profit | €24.91m |
| Other Expenses | €31.99m |
| Earnings | -€7.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 61.31% |
| Net Profit Margin | -17.42% |
| Debt/Equity Ratio | 0% |
How did APPH perform over the long term?
See historical performance and comparison